Pfizer to supply 40M COVID-19 shots for poor countries
Pfizer has committed to supply up to 40 million doses of its COVID-19 vaccine this year to a global effort to get affordable shots to poor and middle-income countries
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Pfizer on Friday committed to supply up to 40 million doses of its COVID-19 vaccine this year to a World Health Organization-backed effort to get affordable shots to poor and middle-income countries
The deal is a boost to the global program known as COVAX, as wealthy nations have snapped up most of the millions of coming shots.
The commitment, announced at a virtual press conference held by the Geneva-based WHO, is seen as important because Pfizer and its partner BioNTech won the first emergency authorization from the influential U.S. Food and Drug Administration in mid-December. That clearance makes it easier for international health groups and poor nations to quickly OK emergency use.
Earlier this week, WHO Director-General Tedros Adhanom Ghebreyesus criticized drugmakers for seeking profits from the pandemic and mostly supplying wealthy countries.
The 40 million doses — for a vaccine requiring two doses — are a tiny sliver of what's needed for COVAX, which aims to vaccinate billions of people in 92 low- and middle-income countries.
The global program previously secured access to nearly 2 billion doses of vaccines from five other vaccine producers, plus options on a billion doses more.
New York-based Pfizer Inc. had not previously committed to providing its COVID-19 vaccine to poor countries without making a profit during the pandemic, as a couple rivals have.
However, Pfizer and Germany’s BioNTech said they would provide their vaccine to COVAX at an undisclosed “not-for-profit price.” The companies still must execute a supply agreement covering distribution, but the doses are to be delivered throughout 2021, starting by the end of March.
“We share the mission of COVAX and are proud to work together so that developing countries have the same access as the rest of the world, which will bring us another step closer to ending this global pandemic,” Pfizer Chief Executive Officer Albert Bourla said in a statement.
Dr. Seth Berkley, CEO of GAVI, the Vaccine Alliance, which is leading procurement and delivery of vaccines for COVAX, called the deal “a major step forward for equitable access to vaccines.”
Pfizer and BioNTech said they would also help health systems handle the vaccine, which requires ultracold storage.
Many public health officials have expressed skepticism that the Pfizer vaccine could be successfully kept so cold across the globe. Pfizer has been shipping the shots in special containers with dry ice, but even in the U.S. some doses have been thrown out because they weren't kept at the proper temperature.
Pfizer has said it’s been ramping up production and expects to be able to make 2 billion doses in 2021, up from its earlier forecast of 1.3 billion doses. That long-term goal comes with a short-term cost: The company is slowing production at its Belgium factory while it makes changes needed to boost production.
___
Follow Linda A. Johnson on Twitter: @LindaJ_onPharma